Literature DB >> 17314222

Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii.

Dror Marchaim1, Shiri Navon-Venezia, David Schwartz, Jalal Tarabeia, Iris Fefer, Mitchell J Schwaber, Yehuda Carmeli.   

Abstract

Isolating carriers of multidrug-resistant (MDR) Acinetobacter baumannii is the main measure to prevent its spread. Identification of carriers accompanied by contact precautions is essential. We aimed to determine the appropriate surveillance sampling sites and the duration of carriage of MDR A. baumannii. We studied prospectively two groups of patients from whom MDR A. baumannii was previously isolated: (i) those with recent clinical isolation (<or=10 days) and (ii) those with remote clinical isolation (>or=6 months). Screening for carriage was conducted from six sites: nostrils, pharynx, skin, rectum, wounds, and endotracheal aspirates. Strains recovered concurrently from different sites were genotyped using pulsed-field gel electrophoresis. Twelve of 22 with recent clinical isolation of MDR A. baumannii had >or=1 positive screening culture, resulting in a sensitivity of 55% when six body sites were sampled. Sensitivities of single sites ranged from 13.5% to 29%. Among 30 patients with remote clinical isolation, screening cultures were positive in 5 (17%), with a mean duration of 17.5 months from the last clinical culture. Remote carriers had positive screening cultures from the skin and pharynx but not from nose, rectum, wounds, or endotracheal aspirates. Eleven strains from five patients were genotyped. In all but one case, isolates from different sites in a given patient were clonal. Current methodology is suboptimal to detect MDR A. baumannii carriage. The sensitivity of surveillance cultures is low, even when six different body sites are sampled. The proportion of individuals with previous MDR A. baumannii isolation who remain carriers for prolonged periods is substantial. These data should be considered when designing measures to limit the spread of MDR A. baumannii.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314222      PMCID: PMC1865886          DOI: 10.1128/JCM.02424-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  27 in total

1.  The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay.

Authors: 
Journal:  Infect Control Hosp Epidemiol       Date:  2002-02       Impact factor: 3.254

Review 2.  The epidemiology and control of Acinetobacter baumannii in health care facilities.

Authors:  Pierre Edouard Fournier; Hervé Richet
Journal:  Clin Infect Dis       Date:  2006-01-26       Impact factor: 9.079

Review 3.  Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem.

Authors:  A S Levin
Journal:  Clin Microbiol Infect       Date:  2002-03       Impact factor: 8.067

Review 4.  Resistance patterns among nosocomial pathogens: trends over the past few years.

Authors:  R N Jones
Journal:  Chest       Date:  2001-02       Impact factor: 9.410

Review 5.  Acinetobacter outbreaks, 1977-2000.

Authors:  Maria Virginia Villegas; Alan I Hartstein
Journal:  Infect Control Hosp Epidemiol       Date:  2003-04       Impact factor: 3.254

Review 6.  Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment.

Authors:  J M Cisneros; J Rodríguez-Baño
Journal:  Clin Microbiol Infect       Date:  2002-11       Impact factor: 8.067

Review 7.  Treatment of Acinetobacter spp infections.

Authors:  Anna S Levin
Journal:  Expert Opin Pharmacother       Date:  2003-08       Impact factor: 3.889

Review 8.  Antimicrobial resistance of Acinetobacter spp. in Europe.

Authors:  M Van Looveren; H Goossens
Journal:  Clin Microbiol Infect       Date:  2004-08       Impact factor: 8.067

9.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

10.  The impact of Acinetobacter baumannii in the intensive care unit.

Authors:  C Theaker; B Azadian; N Soni
Journal:  Anaesthesia       Date:  2003-03       Impact factor: 6.955

View more
  42 in total

Review 1.  Preventing the spread of multidrug-resistant gram-negative pathogens: recommendations of an expert panel of the German Society For Hygiene and Microbiology.

Authors:  Frauke Mattner; Franz-C Bange; Elisabeth Meyer; Harald Seifert; Thomas A Wichelhaus; Iris F Chaberny
Journal:  Dtsch Arztebl Int       Date:  2012-01-20       Impact factor: 5.594

2.  Next-Generation Sequencing and Comparative Analysis of Sequential Outbreaks Caused by Multidrug-Resistant Acinetobacter baumannii at a Large Academic Burn Center.

Authors:  Hajime Kanamori; Christian M Parobek; David J Weber; David van Duin; William A Rutala; Bruce A Cairns; Jonathan J Juliano
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

3.  Laboratory evaluation of the ESwab transport system for the recovery of carbapenem-resistant Acinetobacter baumannii.

Authors:  J Moran-Gilad; D Schwartz; S Navon-Venezia; Y Carmeli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-09       Impact factor: 3.267

Review 4.  Carbapenem-Resistant Non-Glucose-Fermenting Gram-Negative Bacilli: the Missing Piece to the Puzzle.

Authors:  Thomas J Gniadek; Karen C Carroll; Patricia J Simner
Journal:  J Clin Microbiol       Date:  2016-02-24       Impact factor: 5.948

Review 5.  Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.

Authors:  Yohei Doi; Gerald L Murray; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

6.  Population dynamics of an Acinetobacter baumannii clonal complex during colonization of patients.

Authors:  Hanchun Wen; Ke Wang; Yang Liu; Martin Tay; Federico M Lauro; Hong Huang; Huayu Wu; Hongjie Liang; Yichen Ding; Michael Givskov; Yiqiang Chen; Liang Yang
Journal:  J Clin Microbiol       Date:  2014-06-20       Impact factor: 5.948

Review 7.  Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit.

Authors:  Marin H Kollef; Yoav Golan; Scott T Micek; Andrew F Shorr; Marcos I Restrepo
Journal:  Clin Infect Dis       Date:  2011-09       Impact factor: 9.079

8.  Pan-PCR, a computational method for designing bacterium-typing assays based on whole-genome sequence data.

Authors:  Joy Y Yang; Shelise Brooks; Jennifer A Meyer; Robert R Blakesley; Adrian M Zelazny; Julia A Segre; Evan S Snitkin
Journal:  J Clin Microbiol       Date:  2012-12-19       Impact factor: 5.948

9.  Laboratory evaluation of different agar media for isolation of carbapenem-resistant Acinetobacter spp.

Authors:  J Moran-Gilad; A Adler; D Schwartz; S Navon-Venezia; Y Carmeli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-28       Impact factor: 3.267

10.  Multidrug-resistant Acinetobacter baumannii infection, colonization, and transmission related to a long-term care facility providing subacute care.

Authors:  Eva Mortensen; Kavita K Trivedi; Jon Rosenberg; Sara H Cody; Janet Long; Bette J Jensen; Duc J Vugia
Journal:  Infect Control Hosp Epidemiol       Date:  2014-04       Impact factor: 3.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.